Drugs in Inflammation
Published on 1. February 1991
Book
Hardback
260 pages
978-3-7643-2504-6 (ISBN)
Description
On June 28-29, 1990 in Noordwijk, The Netherlands, the International Association of Inflammation societies (IAIS) organized their first symposium on Drugs in Inflammation. The symposium was an official satellite of the Ixth International Congress of Pharmacology (IUPHAR). This volume contains the proceedings from this satellite meeting. The IAIS was constituted in 1988 when representatives of the Inflammation Research Association (IRA), European Workshop on Inflammation (EWI) and British Inflammation Research Association (BIRAs) met at White Haven, Pennsylvania during the Fourth International Conference of the IRA and the group decided that improved communication between inflammation societies could be achieved by establishment of a society. The IAIS would encourage and foster collaboration between the many inflammation societies throughout the world and assist in the establishment of new societies whenever possible. The satellite was a major success thanks to the efforts of the planning committee: Wim van den Berg, the local organizer, Mike Bray, the programme chairman, Rodger McMillan, Greg Harper, Mike Parnham and Kay Brune. In addition, the chairman and presenters ensured the scientific content of the meeting was of a very high standard. Most importantly, the 100 participants from 15 countries made the sessions lively and interactive. The IAIS will hopefully organize additional symposiums in the future. Alan J. Lewis, Ph.D.
More details
Series
Language
English
Place of publication
Basel
Switzerland
Publishing group
Springer Basel
Target group
College/higher education
Professional and scholarly
Illustrations
biography
Dimensions
Height: 240 mm
Weight
650 gr
ISBN-13
978-3-7643-2504-6 (9783764325046)
DOI
10.1007/978-3-0348-7405-2
Schweitzer Classification
Other editions
Additional editions
Michael Parnham | Michael A. Bray | Wim B.van den Berg
Drugs in Inflammation
Book
11/2012
Birkhäuser
€53.49
Shipment within 10-15 days
Content
Reducing the Side-Effects of Anti-Inflammatory Drugs.- Towards safer nonsteroidal anti-inflammatory drugs.- Developing nonsteroidal anti-inflammatory drugs (NSAIDs) with decreased gastrointestinal (GI) toxicity.- Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.- A new anti-inflammatory agent (EGIS-5645) without gastrointestinal side-effect.- Antipyretic activity of tebufelone (NE-11740) in man.- Steroid-saving potency of nonsteroidal anti-inflammatory agents - a reevaluation with the new agent CGP 28238 in rat inflammatory models.- A biochemical investigation of auranofin nephrotoxicity by high field proton nuclear magnetic resonance (NMR) spectroscopy.- Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study.- Influence of disodium aurothiomalate on the activities of xanthine dehydrogenase and xanthine oxidase in endothelial cells.- Application of a novel 1:1 gold (I)-chromophoric thiolate complex as a spectrophotometric probe for the thiol-exchange reactions of anti-arthritic gold drugs in biological fluids.- Effects of auranofin on endothelium dependent contractions in isolated rat aoria.- New Approaches to Pain Relief.- Electrophysiological mechanisms in inflammatory pain.- Molecular base of acetylcholine and morphine analgesia.- Prostaglandin (PG) modulation of bradykinin-induced hyperalgesia and oedema in the guinea-pig paw - effects of PGD2, PGE2 and PGI2.- Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.- Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug.- The pharmacological profile of aceclofenac, a new nonsteroidal anti-inflammatory and analgesic drug.- New Treatments for Bone and Cartilage Loss in Rheumatoid Arthritis.- Molecular basis of intracellular interactions in relation to bone and joint disease.- The role of proteinases in cartilage destruction.- Recognition of IL1-activated chondrocytes in porcine articular cartilage.- In vivo evidence for a key role of IL-1 in cartilage destruction in experimental arthritis.- An anti-CD4 antibody for treatment of chronic inflammatory arthritis.- Modulation of splenic lymphocyte activities by a new hypoxanthine derivative (ST 789) in immunosuppressed mice.- The newly developed neutrophil oxidative burst antagonist apocynin inhibits joint-swelling in rat collagen arthritis.- Auto-immune spondylodiscitis associated with collagen induced arthritis in rats: high field MRI findings.- Influence of muramyl dipeptide on established experimental arthritis in rats.- Selective inhibition by magnosalin and magnoshinin, compounds from "shin-I" (Flos magnoliae), of adjuvant-induced angiogenesis and granuloma formation in the mouse pouch.- Drug Modulation of Cytokine Production.- Cellular and molecular mechanisms of cytokine networking.- Anti-inflammatory properties of E5090, a novel orally active inhibitor of IL-1 generation.- A novel inhibitor of IL-1 generation, E5090: in vitro inhibitory effects on the generation of IL-1 by human monocytes.- A novel inhibitor of IL-1 generation, E5090: in vivo inhibitory effects on the generation of IL-1-like factor and on granuloma formation in an air-pouch model.- Lack of adjuvanticity of human recombinant interleukin-lß in collagen induced arthritis in rats.- Influence of azelastine on IL-1ß generation in vitro and IL-lß-induced effect in vivo.